These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9623326)

  • 21. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
    Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
    Bartel U; Johannsen B; Reiss H; Elling D
    Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma].
    Fínek J; Holubec L; Topolcan O; Pikner R; Sůvová B; Treska V
    Cas Lek Cesk; 2004; 143(3):174-7. PubMed ID: 15134036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients.
    Jäger W; Eibner K; Löffler B; Gleixner S; Krämer S
    Anticancer Res; 2000; 20(6D):5179-82. PubMed ID: 11326691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
    Cheung KL; Graves CR; Robertson JF
    Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
    Heinze T; Lichtenegger W
    Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
    Henry NL; Hayes DF
    Oncologist; 2006 Jun; 11(6):541-52. PubMed ID: 16794234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Standards, options and recommendations for tumor markers in colorectal cancer].
    Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
    Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
    Cheung KL; Robertson FR
    Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
    Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
    Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
    Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
    Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.